{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:53:51Z","timestamp":1740106431792,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK068039","ES006694","ES007091","AT002842","HD062489"],"award-info":[{"award-number":["DK068039","ES006694","ES007091","AT002842","HD062489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["N01-DK-7-0004\/HHSN267200700004C"],"award-info":[{"award-number":["N01-DK-7-0004\/HHSN267200700004C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.taap.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T16:18:29Z","timestamp":1550593109000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis"],"prefix":"10.1016","volume":"368","author":[{"given":"April D.","family":"Lake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhiannon N.","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Leamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2019.02.009_bb0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07853890802552437","article-title":"New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)","volume":"41","author":"Ali","year":"2009","journal-title":"Ann. Med."},{"key":"10.1016\/j.taap.2019.02.009_bb0010","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.taap.2019.02.009_bb0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2009.03.008","article-title":"Kupffer cells in non-alcoholic fatty liver disease: the emerging view","volume":"51","author":"Baffy","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2019.02.009_bb0020","first-page":"221","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.taap.2019.02.009_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004032","article-title":"Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages","volume":"10","author":"Bility","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.taap.2019.02.009_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/srep39520","article-title":"Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation","volume":"6","author":"Bility","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2019.02.009_bb0035","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2019.02.009_bb0040","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d ?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.taap.2019.02.009_bb0045","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/cphy.c120026","article-title":"Kupffer cells in the liver","volume":"3","author":"Dixon","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.taap.2019.02.009_bb0050","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.3748\/wjg.v23.i42.7495","article-title":"Current and emerging pharmacological therapy for non-alcoholic fatty liver disease","volume":"23","author":"Eshraghian","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.taap.2019.02.009_bb0055","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2019.02.009_bb0060","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.26937","article-title":"The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease","volume":"59","author":"Gadd","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2019.02.009_bb0065","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2019.02.009_bb0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2019.02.009_bb0075","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14740338.2017.1343299","article-title":"Treatment options for nonalcoholic steatohepatitis - a safety evaluation","volume":"16","author":"Issa","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.taap.2019.02.009_bb0080","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2019.02.009_bb0085","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.3748\/wjg.v12.i46.7413","article-title":"Role of Kupffer cells in the pathogenesis of liver disease","volume":"12","author":"Kolios","year":"2006","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.taap.2019.02.009_bb0090","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.joca.2016.04.010","article-title":"Direct in vivo evidence of activated macrophages in human osteoarthritis","volume":"24","author":"Kraus","year":"2016","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.taap.2019.02.009_bb0095","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/bc0200430","article-title":"Synthesis and biological evaluation of EC20: a new Folate-derived, 99mTc-based radiopharmaceutical","volume":"13","author":"Leamon","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.taap.2019.02.009_bb0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","article-title":"Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions","volume":"68","author":"Loomba","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2019.02.009_bb0105","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbpa.2009.03.022","article-title":"Folate-targeted therapeutic and imaging agents for cancer","volume":"13","author":"Low","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.taap.2019.02.009_bb0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.addr.2012.09.020","article-title":"Folate-mediated delivery of macromolecular anticancer therapeutic agents","volume":"64","author":"Lu","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.taap.2019.02.009_bb0115","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/ar3304","article-title":"Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate","volume":"13","author":"Lu","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.taap.2019.02.009_bb0120","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2119\/molmed.2015.00040","article-title":"Antiinflammatory activity of a novel folic acid targeted conjugate of the mTOR inhibitor everolimus","volume":"21","author":"Lu","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.taap.2019.02.009_bb0125","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.1501878","article-title":"Folate receptor \u03b2 regulates integrin CD11b\/CD18 adhesion of a macrophage subset to collagen","volume":"197","author":"Machacek","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.taap.2019.02.009_bb0130","article-title":"Pathogenesis of nonalcoholic Steatohepatitis: interactions between liver parenchymal and nonparenchymal cells","volume":"11","author":"Magee","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.taap.2019.02.009_bb0135","first-page":"4465","article-title":"Prognostic significance of CD68, CD163 and Folate receptor-\u03b2 positive macrophages in hepatocellular carcinoma","volume":"15","author":"Minami","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.taap.2019.02.009_bb0140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2019.02.009_bb0145","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood.V93.11.3940","article-title":"Expression and functional characterization of the \u03b2-isoform of the Folate receptor on CD34(+) cells","volume":"93","author":"Reddy","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.taap.2019.02.009_bb0150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5306\/wjco.v8.i6.429","article-title":"Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"8","author":"Said","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.taap.2019.02.009_bb0155","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10555-008-9155-6","article-title":"Tumor detection using folate receptor-targeted imaging agents","volume":"27","author":"Sega","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.taap.2019.02.009_bb0160","doi-asserted-by":"crossref","first-page":"14700","DOI":"10.18632\/oncotarget.3739","article-title":"Assessment of folate receptor-beta expression in human neoplastic tissues","volume":"6","author":"Shen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2019.02.009_bb0165","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated Rapamycin slows progression of polycystic kidney disease","volume":"23","author":"Shillingford","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.taap.2019.02.009_bb0170","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gut.2005.071118","article-title":"Tumour necrosis factor \u03b1 signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice","volume":"55","author":"Tomita","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.taap.2019.02.009_bb0175","doi-asserted-by":"crossref","first-page":"40161","DOI":"10.1074\/jbc.M112.417014","article-title":"Kuppfer cells trigger nonalcoholic Steatohepatitis development in diet-induced mouse model through tumor necrosis factor-\u03b1 production","volume":"287","author":"Tosello-Trampont","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2019.02.009_bb0180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/apt.14210","article-title":"Review article: new treatments in non-alcoholic fatty liver disease","volume":"46","author":"Townsend","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2019.02.009_bb0185","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/mp0700615","article-title":"Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus","volume":"4","author":"Varghese","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.taap.2019.02.009_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"68","author":"Younossi","year":"2017","journal-title":"Hepatology"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19300584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19300584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T03:15:46Z","timestamp":1662952546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X19300584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":38,"alternative-id":["S0041008X19300584"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2019.02.009","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}